{"disease":{"id":"prevention-of-poliomyelitis","name":"prevention of poliomyelitis"},"drugs":{"marketed":[{"drug_id":"dtacp-ipv-combined-vaccine-tetraxim","indication_name":"Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in children 6 weeks through 6 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DTacP-IPV combined vaccine (TETRAXIM™)","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3","drug_class":"Combination inactivated vaccine","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}